Pyxis Oncology (NASDAQ:PYXS) Announces Earnings Results, Misses Expectations By $0.02 EPS

Pyxis Oncology (NASDAQ:PYXS) posted its quarterly earnings data on Thursday. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02), Zacks reports.

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS traded down $0.41 during midday trading on Thursday, reaching $2.21. The company’s stock had a trading volume of 1,062,627 shares, compared to its average volume of 571,989. Pyxis Oncology has a fifty-two week low of $0.97 and a fifty-two week high of $5.55. The firm has a 50 day moving average price of $1.70 and a two-hundred day moving average price of $2.30. The firm has a market capitalization of $138.90 million, a price-to-earnings ratio of -1.71 and a beta of 1.43.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on PYXS shares. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research report on Tuesday, March 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. Wedbush initiated coverage on Pyxis Oncology in a research note on Tuesday, May 5th. They issued an “outperform” rating and a $6.00 price objective on the stock. Stifel Nicolaus reduced their target price on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, March 24th. Finally, Wall Street Zen upgraded shares of Pyxis Oncology from a “sell” rating to a “hold” rating in a report on Monday, April 13th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $6.83.

Institutional Investors Weigh In On Pyxis Oncology

Hedge funds have recently added to or reduced their stakes in the business. Maia Wealth LLC acquired a new position in Pyxis Oncology in the fourth quarter valued at approximately $25,000. Engineers Gate Manager LP acquired a new stake in shares of Pyxis Oncology during the 4th quarter worth approximately $26,000. Fox Run Management L.L.C. bought a new stake in shares of Pyxis Oncology in the 4th quarter valued at $26,000. XTX Topco Ltd bought a new stake in shares of Pyxis Oncology in the 2nd quarter valued at $40,000. Finally, LPL Financial LLC lifted its position in shares of Pyxis Oncology by 150.7% during the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock valued at $40,000 after acquiring an additional 21,100 shares during the period. 39.07% of the stock is currently owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.